Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
18
×
national blog main
18
×
national top stories
san francisco blog main
18
×
startups
18
×
life sciences
new york blog main
biotech
boston blog main
san diego blog main
san diego top stories
detroit blog main
detroit top stories
new york top stories
raleigh-durham blog main
san francisco top stories
wisconsin blog main
boston top stories
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
deals
indiana blog main
indiana top stories
national
clinical trials
eli lilly
fda
cancer immunotherapy
alzheimer's disease
investing
ipo
takeda pharmaceutical
abbvie
biogen
What
roundup
bio
drug
companies
drugs
new
week
cancer
fda
ipo
life
medicines
pharmaceutical
sciences
acquisitions
advance
ahead
alzheimer’s
annual
asco
attention
biology
biotech
black
buy
cash
ceo
company
covid
cytokine
daniel
days
debut
diamond’s
enhanced
gilead
growing
lead
merck
moves
Language
unset
Current search:
startups
×
" san francisco blog main "
×
" national blog main "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Pfizer, Merck Lead Strata Oncology’s $26M Series B Round
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs